Ureteroscopy After Recent Apixaban Dose
Ureteroscopy for stone removal can generally be performed with minimal interruption or even with continuation of oral anticoagulant therapy in selected patients. [1], [2] For perioperative DOAC management guidance, apixaban is typically stopped 1–2 days before an elective procedure and resumed about 24 hours after a low/moderate bleeding-risk procedure. [3]
Periprocedural Apixaban Timing Recommendations
Apixaban (Eliquis) should be discontinued at least 24 hours before elective procedures with a low bleeding risk when bleeding is noncritical and easily controlled. [4] CHEST guidance for elective surgery suggests stopping a DOAC such as apixaban for 1 to 2 days before the procedure. [3] Postoperatively, CHEST guidance suggests resuming the DOAC about 24 hours after a low/moderate-bleed-risk procedure. [3]
Ureteroscopy Bleeding-Risk Considerations
Ureteroscopy is described as a procedure that can be performed with continuing oral anticoagulant or antiplatelet therapy in urologic white-paper guidance. [2] European Association of Urology guidance states that ureteroscopy is safe in patients with bleeding disorders or anticoagulation, while emphasizing an individualized approach. [1]
Practical Interpretation for a 24-Hour Interval After the Last Dose
A procedure performed 24 hours after the last apixaban dose is consistent with product labeling statements for low bleeding-risk elective procedures. [4] This timing is also consistent with the general DOAC strategy of withholding for approximately 1 day before low/moderate bleeding-risk operations, with resumption after ensuring hemostasis. [3]
Factors That Require Individualized Adjustment
Patient-specific factors that increase apixaban exposure or bleeding risk include renal dysfunction and other clinical bleeding risk features. [5] Procedural factors that increase bleeding concern include operative complexity, anticipated mucosal injury, and inability to achieve secure hemostasis. [3] When interruption is required for higher bleeding-risk circumstances, CHEST guidance supports longer preoperative interruption for higher-bleed-risk procedures than for low/moderate-bleed-risk procedures. [3]
Common Pitfalls to Avoid
Scheduling the procedure without confirming expected bleeding risk classification and ability to achieve hemostasis increases the likelihood of perioperative bleeding when DOAC interruption has not been adequate. [3] Resuming apixaban earlier than 24 hours after a low/moderate bleeding-risk procedure increases bleeding risk. [3]
Clinical Decision Framework for This Scenario
If ureteroscopy is judged to be low/moderate bleeding risk with an expectation of secure hemostasis, performing ureteroscopy about 24 hours after the last apixaban dose is consistent with apixaban labeling and perioperative DOAC guidance. [3], [4] If ureteroscopy is judged to involve higher bleeding risk or if patient factors increase bleeding risk, an interval longer than 24 hours after the last apixaban dose is supported by DOAC perioperative interruption guidance. [3]
Target Outcomes
The perioperative objective is secure surgical hemostasis before DOAC resumption, with DOAC restart timing aligned to the procedure’s bleeding risk category. [3]